Vaccine Medical, Development, Scientific and Clinical Affairs, Pfizer Inc, Collegeville, PA, USA.
Dr. Horst Schmidt Clinic, Children's Hospital, Wiesbaden, Germany, and Pediatric Infectious Diseases, University Medicine, Mainz, Germany.
Hum Vaccin Immunother. 2021 Jul 3;17(7):2205-2215. doi: 10.1080/21645515.2020.1855952. Epub 2021 Feb 19.
Many countries are replacing meningococcal serogroup C (MenC) conjugate vaccines (MCCV) with quadrivalent conjugate (MenACWY) vaccines, such as MenACWY-TT (Nimenrix®). This review examined eight studies comparing MenC immune responses induced by MenACWY-TT and MCCV to determine if these data support these changes. MenC serum bactericidal antibody levels using human (hSBA) or rabbit complement (rSBA) were evaluated at ~1 month postvaccination. Overall, ≥98.4% of infants administered 2 + 1 MenACWY-TT or MCCV schedules had rSBA titers ≥1:8 postprimary and postbooster vaccination; hSBA titers ≥1:8 were similar. In toddlers administered single MenACWY-TT or MCCV doses, ≥97.3% had rSBA titers ≥1:8 postvaccination; percentages with hSBA titers ≥1:8 were higher post-MenACWY-TT. Of children and adolescents receiving primary and booster MenACWY-TT and MCCV, ≥98.6% had rSBA titers ≥1:8; all children receiving MenACWY-TT or MCCV booster had hSBA titers ≥1:8 postdosing. MenC immune responses induced by MenACWY-TT are robust and generally comparable/superior to MCCV, supporting changes to recommendations.
许多国家正在用四价结合疫苗（MenACWY）替代脑膜炎奈瑟球菌血清群 C（MenC）结合疫苗（MCCV），如 MenACWY-TT（Nimenrix®）。本综述评估了八项比较 MenACWY-TT 和 MCCV 诱导的 MenC 免疫应答的研究，以确定这些数据是否支持这些变化。在接种后约 1 个月评估了使用人源（hSBA）或兔源补体（rSBA）的 MenC 血清杀菌抗体水平。总体而言，接受 2+1 剂次 MenACWY-TT 或 MCCV 接种方案的婴儿中，≥98.4%的婴儿在初次接种和加强接种后 rSBA 滴度≥1:8；hSBA 滴度≥1:8 相似。在接受单剂次 MenACWY-TT 或 MCCV 的幼儿中，≥97.3%的 rSBA 滴度≥1:8；接受 MenACWY-TT 后 hSBA 滴度≥1:8 的百分比更高。在接受 MenACWY-TT 和 MCCV 初免和加强接种的儿童和青少年中，≥98.6%的 rSBA 滴度≥1:8；所有接受 MenACWY-TT 或 MCCV 加强接种的儿童在接种后 hSBA 滴度均≥1:8。MenACWY-TT 诱导的 MenC 免疫应答强劲，通常与 MCCV 相当/更优，支持推荐的改变。
